You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
晶泰控股(02228.HK)與哈佛教授創立的DoveTree達成合作 首付款1億美元撬動數十億美元潛在里程碑

格隆匯6月23日丨晶泰控股(02228.HK)發佈公告,公司近期與DoveTree LLC(“DoveTree”,一家由Gregory Verdine教授創立的公司)訂立合作意向書。根據合作意向書,(1)集團將利用其基於“AI+機器人”的端到端人工智能藥物發現平臺,爲DoveTree選定的多個針對腫瘤、自身免疫性疾病及神經疾病領域的靶點,發現和開發小分子及抗體類候選藥物,(2)集團將在最終協議簽署的10日及180日內分別獲得5100萬美元及4900萬美元首付款,並有資格獲得金額達數十億美元的潛在開發里程碑及銷售里程碑付款,以及基於產品年度淨銷售額的潛在個位數百分點的特許權使用費,及(3)DoveTree將獲得以上產品全球範圍的獨家開發和商業化權利。

Gregory Verdine教授乃哈佛大學化學系終身教授,爲化學生物學的先驅,亦爲傑出連續創業家。彼闡明瞭表觀遺傳DNA甲基化的分子機制,併爲新型治療模式領域的領軍人物。作爲創業領軍人物,Verdine教授創立或共同創立了超過十家生物科技公司,包括五家公開上市公司。彼主導推進的三種治療方法已獲FDA批準。Verdine教授現擔任Andreessen Horowitz (a16z)的投資合夥人,其顧問委聘方包括美國國家癌症研究所及哈佛醫學院等頂尖研究機構。

集團致力於透過集成“AI+機器人”技術,提供藥物發現及材料科學研發解決方案及服務。倘合作意向書項下擬進行的交易得以落實,將進一步增強集團“AI+機器人”智能自主實驗平臺在藥物發現領域的實力,以期爲世界各地的患者帶來突破性療法。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account